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Introduction {#pri1625-sec-0005}
============

Many people with multiple sclerosis (PwMS) experience falls (Cattaneo *et al*., [2002](#pri1625-bib-0003){ref-type="ref"}; Finlayson *et al*., [2006](#pri1625-bib-0006){ref-type="ref"}; Nilsagard *et al*., [2009b](#pri1625-bib-0023){ref-type="ref"}; Kasser *et al*., [2011](#pri1625-bib-0012){ref-type="ref"}; Matsuda *et al*., [2011](#pri1625-bib-0017){ref-type="ref"}; Prosperini *et al*., [2011](#pri1625-bib-0028){ref-type="ref"}; Coote *et al*., [2013](#pri1625-bib-0004){ref-type="ref"}; Gunn *et al*., [2013a](#pri1625-bib-0009){ref-type="ref"}), and falls often occur when walking and transferring (Cattaneo *et al*., [2002](#pri1625-bib-0003){ref-type="ref"}; Finlayson *et al*., [2006](#pri1625-bib-0006){ref-type="ref"}; Nilsagard *et al*., [2009a](#pri1625-bib-0022){ref-type="ref"}; Matsuda *et al*., [2011](#pri1625-bib-0017){ref-type="ref"}). Gait impairment (Benedetti *et al*., [1999](#pri1625-bib-0001){ref-type="ref"}, Martin *et al*., [2006](#pri1625-bib-0016){ref-type="ref"}) and fall tendency are present early in the disease course (Moen *et al*., [2011](#pri1625-bib-0019){ref-type="ref"}). Reduced stride length, prolonged double support phase, altered muscular recruitment and reduced speed have been reported in people with mild MS, that is values between 0 and 2.5 according to the Expanded Disability Status Scale (EDSS) (Benedetti *et al*., [1999](#pri1625-bib-0001){ref-type="ref"}; Martin *et al*., [2006](#pri1625-bib-0016){ref-type="ref"}). Being able to walk longer distances is required for many everyday tasks and participation in society. Increased dependency in self‐care, mobility and domestic life are reported as associated with a shorter distance covered during the 6‐minute walk test (6MWT) (Paltamaa *et al*., [2007](#pri1625-bib-0024){ref-type="ref"}). The importance of walking distance is also recognized when determining MS severity using scales, such as EDSS (Kurtzke, [1983](#pri1625-bib-0014){ref-type="ref"}).

The presence of motor, sensor or cognitive symptoms have been suggested to be associated with falls in PwMS (Cattaneo *et al*., [2002](#pri1625-bib-0003){ref-type="ref"}; Finlayson *et al*., [2006](#pri1625-bib-0006){ref-type="ref"}; Nilsagard *et al*., [2009a](#pri1625-bib-0022){ref-type="ref"}; Nilsagard *et al*., [2009b](#pri1625-bib-0023){ref-type="ref"}; Cameron and Wagner, [2011](#pri1625-bib-0002){ref-type="ref"}; Kasser *et al*., [2011](#pri1625-bib-0012){ref-type="ref"}; Matsuda *et al*., [2011](#pri1625-bib-0017){ref-type="ref"}; Prosperini *et al*., [2011](#pri1625-bib-0028){ref-type="ref"}; Prosperini *et al*., [2013](#pri1625-bib-0027){ref-type="ref"}; Sosnoff *et al*., [2013](#pri1625-bib-0034){ref-type="ref"}), and these symptoms may also impact walking ability. Kasser and co‐workers reported that temporo‐spatial changes were frequent in recurrent fallers (Kasser *et al*., [2011](#pri1625-bib-0012){ref-type="ref"}), while D\'Orio reported a significant correlation (*r* = 0.39) between walking speed and falls (D\'Orio *et al*., [2012](#pri1625-bib-0005){ref-type="ref"}). Walking capacity is increasingly limited with more advanced MS, displayed as a changed gait pattern and reduced speed (Kelleher *et al*., [2010](#pri1625-bib-0013){ref-type="ref"}). Moreover, the need for a walking aid increases in the progressive phase of the disease. An association between use of mobility aid and falls has been reported in a recently published meta‐analysis (Gunn *et al*., [2013b](#pri1625-bib-0010){ref-type="ref"}).

Although falls and fall tendency are associated with disease severity (Nilsagard *et al*., [2009b](#pri1625-bib-0023){ref-type="ref"}; Moen *et al*., [2011](#pri1625-bib-0019){ref-type="ref"}; Prosperini *et al*., [2011](#pri1625-bib-0028){ref-type="ref"}; Sosnoff *et al*., [2012](#pri1625-bib-0035){ref-type="ref"}; Prosperini *et al*., [2013](#pri1625-bib-0027){ref-type="ref"}), people with moderate mobility restrictions are reported to fall more frequently than those with modest or severe mobility restrictions (Matsuda *et al*., [2012](#pri1625-bib-0018){ref-type="ref"}).

The high frequency of falls and fallers in the MS community stresses the need for accurate clinical assessment tools in identifying potential fallers. For example, a possible association between walking distance, as a measure of endurance, and fall risk is yet to be evaluated. Until now, the association between walking ability and fall risk has been investigated using different scales (Cattaneo *et al*. [2002](#pri1625-bib-0003){ref-type="ref"}; Nilsagard *et al*., [2009b](#pri1625-bib-0023){ref-type="ref"}) or by temporal--spatial parameters of gait (Kasser et al. [2011](#pri1625-bib-0012){ref-type="ref"}). Actual walking distance is rarely measured in clinical practise. Instead, one relies on patient self‐estimation. Reduced muscular endurance has been recognized by PwMS as an increasing fall risk and being aware of one\'s limits is identified as a strategy to prevent falls (Nilsagard *et al*., [2009a](#pri1625-bib-0022){ref-type="ref"}). In the present study, we investigated if walking distance and patient estimate of walking distance are possible predictors of fall in PwMS. We hypothesized that reduced walking distance and overestimation of walking distance would be associated with falls.

Methods {#pri1625-sec-0006}
=======

Design {#pri1625-sec-0007}
------

A prospective study was conducted, with a single test occasion followed by prospective registration of falls for 3 months.

Outcome variable {#pri1625-sec-0008}
----------------

Self‐reported falls defined as 'any unexpected event resulting in the person landing on the floor or lower level' (Lamb *et al*., [2005](#pri1625-bib-0015){ref-type="ref"}). A faller was defined by reporting ≥1 fall during a 3‐month period.

Predictor variables {#pri1625-sec-0009}
-------------------

The 6MWT has been recommended as a measure of performance of walking endurance in PwMS (Goldman *et al*., [2010](#pri1625-bib-0008){ref-type="ref"}; Motl *et al*., [2013](#pri1625-bib-0020){ref-type="ref"}). The distance covered reduces with increasing EDSS, but the test is well tolerated also with more severe walking disability (Goldman *et al*., [2008](#pri1625-bib-0007){ref-type="ref"}; Motl *et al*., [2012](#pri1625-bib-0021){ref-type="ref"}). The 6MWT incorporates both anaerobic and aerobic work, with steady state reached the last three minutes (Motl *et al*., [2012](#pri1625-bib-0021){ref-type="ref"}).The 6MWT correlates well with self‐reported perceived limitations of walking capacity (Goldman *et al*., [2008](#pri1625-bib-0007){ref-type="ref"}) and balance confidence (Wetzel *et al*., [2011](#pri1625-bib-0037){ref-type="ref"}), and intra‐rater and inter‐rater reliability are reported as excellent (Intraclass Correlation Coefficient 0.95 and 0.91, respectively). The study participants were encouraged to walk as fast they could back and forth in a quiet hallway with a 30‐m interval for a maximum of 15 minutes. No encouragement was given during the test procedure and sitting rest was not allowed, according to the description by Goldman *et al*. (Goldman *et al*., [2008](#pri1625-bib-0007){ref-type="ref"}). Distance was measured at 6 minutes (6MWT) and after 15 minutes (if able to walk ≥15 minutes) or when the participant had reached his or her maximal distance within the predetermined time limit. Walking distance was measured using a minimum of walking device in accordance with the EDSS grading. A correct patient self‐estimate of maximal walking distance was defined as an agreement between estimated and actually measured distance walked ±10% (Ringel and Zettl, [2006](#pri1625-bib-0030){ref-type="ref"}).

Ethical consideration {#pri1625-sec-0010}
---------------------

The study was approved by the Regional Ethics Committee in Uppsala, Sweden (2012/077), and followed the Helsinki Declaration. The participants gave written‐informed consent.

Subjects {#pri1625-sec-0011}
--------

All PwMS who were resident in Region Örebro County and with a previously registered EDSS between 3.0 and 7.0 in the Swedish MS Registry were invited to participate (*n* = 149). Inclusion criteria were the following: 1) relapse‐free for at least 3 months prior to study entry; 2) able to understand verbal and written information and 3) preserved ability to walk with or without use of walking devices. The exclusion criterion was the following: other diseases or conditions with impact on walking ability (for example other neurological diseases, severe ischemic heart disease and orthopaedic conditions).

Out of 149 eligible PwMS, 54 accepted to participate and were initially believed to fulfil the criteria. As discovered during the test procedure, two of them were not able to walk and one did not fulfil the diagnostic criteria for MS. Another two did not return any fall diaries. Thus, the final sample consisted of 49 PwMS (Table [1](#pri1625-tbl-0001){ref-type="table"}). Fall data were obtained for 49, 47 and 46 PwMS in the first, second and third month, respectively. Data regarding fall circumstances were missing in two cases.

###### 

Demographics and sample characteristics for the entire MS sample and for non‐fallers and fallers separately

  Variable                                         Total (*n* = 49)       Non‐faller (*n* = 27)   Faller (*n* = 22)  
  ------------------------------------------- -------------------------- ----------------------- ------------------- ----------------
  Age, years : mean;                                                            55.6 (11)             54.1 (11)         57.5 (10)
  SD range                                                                       22; 73                22; 70             32; 73
  Sex (frequency)                                        Male                   11 (22%)               7 (26%)           4 (18%)
                                                        Female                  38 (78%)              20 (74%)           18 (82%)
  BMI : mean; SD                                                                 26 (4)                27 (5)             26 (4)
  EDSS median, (25--75% IQR)                                                 4.5 (4.0--6.5)        4.5 (4.0--6.5)     5.0 (4.0--6.5)
  MS subtype (frequency)                                 RRMS                   21 (43%)              13 (48%)           8 (36%)
                                                      SPMS/PPMS                 28 (57%)              14 (52%)           14 (64%)
  SDMT score:                                                                   *n* = 48              *n* = 26       
  mean; SD                                                                       41 (14)               44 (15)           38 (12)
  Cognitive dysfunction (PASAT): *n* = 44                Yes                    22 (46%)              12 (44%)           10 (46%)
  Cognitive dysfunction(FSMC): (frequency)        None or mild (≤52)             7 (14%)               2 (7%)            5 (23%)
                                               Moderate or Severe (≥53)         42 (86%)              25 (93%)           17 (77%)
  Walk aid (frequency)                                   Yes                    17 (35%)               8 (30%)           9 (40%)
  Maximal walk test (metres):                                                                                        
  mean; SD                                                                      531 (452)             607 (506)         438 (366)
  median; range                                                               374 (5; 1530)        381 (34; 1530)     278 (5; 1239)
  6‐minute walk test (metres):                                                  *n* = 43              *n* = 23           *n* = 20
  mean, SD                                                                      316 (145)             355 (154)         272 (121)
  median; range                                                               314 (5; 616)          374 (70; 616)      270 (5; 513)
  Overestimated walking distance(frequency)                                     10 (20%)               5 (18%)           5 (23%)
  MSWS‐12 score                                                                                                      
  (0--100): mean, SD                                                             63 (28)               60 (31)           66 (23)
  median; range                                                                69 (42--88)           69 (33--88)       70 (47--83)

*n* = 49 (27:22) unless otherwise stated. EDSS = Expanded Disability Status Scale; IQR = inter‐quartile range; BMI = Body Mass Index; SPMS = secondary progressive MS; PPMS = primary progressive MS; FSMC = Fatigue Scale for Motor and Cognitive Functions; SDMT = Symbol Digit Modalities Test; PASAT = Paced Auditory Serial Addition Test; MSWS‐12 = 12‐item Multiple Sclerosis Scale; RRMS = Relapsing‐remitting MS.

Procedure {#pri1625-sec-0012}
---------

The testing procedure was performed at Örebro University Hospital using standardized protocols. Neurological examination was performed for re‐assessment and validation of the previously registered EDSS score. The neurologist asked the participants to estimate the distance they could walk at their best, in accordance with EDSS‐rating procedure, and noted the exact estimation. Furthermore, data on demographics and medical history, such as disease phenotype, were collected. To further describe the sample and to collect data on possible confounders, measures of cognitive processing speed previously related to falls in MS were used (D\'Orio *et al*., [2012](#pri1625-bib-0005){ref-type="ref"}; Sosnoff *et al*., [2013](#pri1625-bib-0034){ref-type="ref"}). Firstly, the Symbol Digit Modality Test (SDMT) that measures the number of correct number--geometric symbol pairings provided for 90 seconds (Smith, [1982](#pri1625-bib-0033){ref-type="ref"}). Secondly, the Paced Auditory Serial Addition Test (PASAT‐3) that requires the person to add auditory presented digits to a proceeding given digit and verbally state the sum (Rao, [1990](#pri1625-bib-0029){ref-type="ref"}). The number of correct given answers forms a score. To describe the perceived limitations of walking due to MS, the 12‐item MS Walking Scale score (0--100) was used, and higher scores indicate more pronounced perceived limitations (Hobart *et al*., [2003](#pri1625-bib-0011){ref-type="ref"}). Finally, the Fatigue Scale for Motor and Cognitive Functions (FSMC) was used (Penner *et al*., [2009](#pri1625-bib-0025){ref-type="ref"}).

Thereafter, a physiotherapist experienced in neurology assessed the walking ability and handed out a falls diary with the instruction to register falls during a 3‐month period. Additional information (location, time of day, activity and injuries) was filled in for each fall. An upper limit for reporting was set to four falls per month for the participants\' convenience. The diaries were returned on a monthly basis and if not received by the physiotherapist, reminder phone calls and letters were applied.

Statistical procedure {#pri1625-sec-0013}
---------------------

Logistic regression analyses were performed with fallen/not fallen as dependent variable and for each predictor variable. The results are presented as Odds ratios (OR) with 95% confidence intervals, *p*‐values and area under the receiving operating curve with 95% confidence intervals. ORs for continuous variables with large heterogeneity were calculated and divided with 100 to illustrate the risk if increased by one step (100 m) for walking test performance. *p*‐values, OR and area under the receiving operating curve are based on original values and not on stratified groups. The Statistical Package for the Social Sciences, version 15.0 (SPSS Inc., Chicago, IL, USA) was used to analyse the data.

Results {#pri1625-sec-0014}
=======

Altogether, 22 PwMS (47%) were classified as fallers, providing information of 66 falls in total. Fourteen (29%) reported two falls or more. The mean score of perceived limitation in walking measured using the MSWS‐12 was 63 (SD 28) (Table [1](#pri1625-tbl-0001){ref-type="table"}). Only two had primary progressive MS (one faller and one non‐faller), and only one used a unilateral walk aid (faller). Twenty‐one PwMS (43%) estimated their maximal walking distance correctly (within ±10%): 11 (41%) fallers and 10 (46%) non‐fallers, while 18 PwMS (37%) underestimated their maximal walking distance: 11 (41%) fallers and 7 (32%) non‐fallers.

Fifteen falls were reported to result in minor injuries (pain, bruise and wound). The majority of falls occurred in the afternoon (12.00--17.59 [pm]{.smallcaps}; *n* = 35), while falls were more rare in the hours 06.00--11.59 [am]{.smallcaps} (*n* = 17) and 18.00--23.59 [pm]{.smallcaps} (*n* = 10). Only one fall occurred between 24.00 and 05.59 [am]{.smallcaps}. Forty‐seven of the falls occurred at home (inside or outside). The most common activities performed when falling were walking (*n* = 17), turning (*n* = 12), transferring (*n* = 11) and standing (*n* = 6). The falls were primarily reported to be caused by loss of balance (*n* = 32), followed by legs gave away (*n* = 9), fatigue (*n* = 9), distraction (*n* = 6) and dizziness (*n* = 4). Three falls each were caused by stumbling, slipping, reduced vision or when affected by heat. Seven falls occurred in public buildings, six on driveway or lawn, three on the street and three in a shop.

Data were available for 43 PwMS who completed the 6MWT. The ORs for the investigated variables were non‐significant (Table [2](#pri1625-tbl-0002){ref-type="table"} and Figure [1](#pri1625-fig-0001){ref-type="fig"}). The 6MWT was near significant (*p* = 0.066) suggesting that if the distance walked during 6 minutes increases with 100 metres, the risk of being classified as a faller is reduced by 36%.

###### 

Odds Ratio, *p*‐value and area under the receiving operating curve with 95% confidence intervals for walk test data and overestimation of walking distance

  Variable                                 Value[a](#pri1625-note-0003){ref-type="fn"}   no. of fallers (%)   Faller OR (95%CI)   *p*‐value           AUROC (95%CI)
  ---------------------------------------- --------------------------------------------- -------------------- ------------------- ------------------- -------------------
  Maximal walk test (/100 m)               0.05--\<2.43                                  9 (53)                                                       
                                           2.43--\<6.5                                   7 (44)                                                       
  6.5--15.3                                6 (38)                                        0.92 (0.80--1.05)    0.195               0.59 (0.43--0.75)   
  6MWT (/100 m)                            0.05--\<2.46                                  8 (57)                                                       
                                           2.46--\<3.81                                  8 (57)                                                       
  3.81--6.16                               4 (27)                                        0.64 (0.40--1.03)    0.066               0.67 (0.50--0.83)   
  Overestimated maximal walking distance                                                 5 (50)               1.27 (0.59--2.74)   0.537               0.55 (0.40--0.70)

OR = odds ratio; CI = confidence intervals; AUROC = Area under the Receiving Operating Curve; 6MWT = 6‐minute walk test.

Categories for categorical variables and subgroups for continuous variables.

![Forrest plot for the 6‐minute walk test, maximal walking distance and overestimated walking distance](PRI-21-102-g001){#pri1625-fig-0001}

Discussion {#pri1625-sec-0015}
==========

Aiming to examine putative predicators of fall risk in MS, we addressed walking performance and estimation of maximal walking distance. In the present MS sample, we did not obtain any significant differences comparing fallers and non‐fallers regarding the examined walking parameters. The investigated sample was considered to be representative in terms of fall frequency since 47% of the PwMS experienced falls during a 3‐month period, in line with previous studies (Cattaneo *et al*., [2002](#pri1625-bib-0003){ref-type="ref"}; Finlayson *et al*., [2006](#pri1625-bib-0006){ref-type="ref"}; Nilsagard *et al*., [2009b](#pri1625-bib-0023){ref-type="ref"}; Kasser *et al*., [2011](#pri1625-bib-0012){ref-type="ref"}; Matsuda *et al*., [2011](#pri1625-bib-0017){ref-type="ref"}; Prosperini *et al*., [2011](#pri1625-bib-0028){ref-type="ref"}; Coote *et al*., [2013](#pri1625-bib-0004){ref-type="ref"}; Gunn *et al*., [2013a](#pri1625-bib-0009){ref-type="ref"}). The sex distribution was also compatible of that expected in a MS population.

Several factors may impact walking, and it was believed that these factors may be reflected by testing walking capacity over a longer distance. Tests, such as the 6MWT, may also minimize the risk of overlooking motor fatigue or ceiling effects using shorter distances, especially for people with mild MS (van Winsen *et al*., [2010](#pri1625-bib-0036){ref-type="ref"}). Motor fatigue is described as a gradual decline of the maximal muscle strength during a constant mild to moderate exercise (Phan‐Ba *et al*., [2012](#pri1625-bib-0026){ref-type="ref"}), and the 6MWT is suggested to capture motor fatigue, that is reduced speed at the end of the test (Goldman *et al*., [2008](#pri1625-bib-0007){ref-type="ref"}).

Walking tests in general are mainly developed based on situations where falls are less likely to occur, that is performed during controlled environmental circumstances. Falls related to dual tasking or with environmental challenges are possibly insufficiently captured with such tests although concomitant cognitive tasks can be used (Shumway‐Cook *et al*., [2000](#pri1625-bib-0031){ref-type="ref"}). From a clinical perspective, a measure that combines endurance, dual tasking and environmental challenges would probably be more stringent as a predictor of falls. It would be interesting to use the 6MWT outdoors to meet these challenges.

Moreover, patients that overestimated their maximal walking distance were not overrepresented among fallers. The estimation of walking distance was done before the test procedure, and the participants were unaware of how long the corridor was during testing. This implies that they were neither helped in their estimation by having performed the test nor could adjust their actual walking distance to fit their estimation. In the present study, a larger proportion correctly estimated (43%) their actual walking distance compared with that reported by Ringel and co‐workers (21%) (Ringel and Zettl, [2006](#pri1625-bib-0030){ref-type="ref"}).

According to our knowledge, maximal walking distance rarely is included as an objective test in clinical practice. One plausible reason is that it is time consuming from both patients and the care givers perspectives and may be exhausting for the patients. The value of objective testing must be scrutinized before incorporated as standardized parameter in clinical assessment.

Despite the fact of a small sample (*n* = 49), our data suggest that the investigated parameters have limited clinical relevance in identifying fallers among individuals with MS. Further studies may yield additional information in terms of walking speed over longer distances, because we observed a predictive trend in 6MWT data analysis (*p* = 0.066). A post‐power size calculation was made for the 6MWT. Based on a clinically significant difference between groups at 60, the assumption of an equal standard deviation at 140, an allocation to a group of faller or non‐faller at 1:1 and a power at 80%, the sample size has to be 87 persons in each group.

A majority of falls in this study were perceived to be caused simply by loss of balance. An alternative approach in further examination of fall risk in MS may be to study other parameters which influence on walking ability, rather than focus on the maximal walking distance itself. The variation in maximal walking distance suggests difficulties finding clinically relevant cutoffs to predict who will fall or not. Although the most commonly reported activity performed when falling was "walking" in the present study, the results imply that maximal walking distance *per se* is not associated with falls. Instead, underlying factors affecting walking, that is spasticity, proprioception and muscular strength, are of greater importance. However, neither maximal walking distance nor patient overestimate of walking distance in PwMS was associated with falls.

Study limitations {#pri1625-sec-0016}
-----------------

There were several study limitations. Due to safety reasons, the physiotherapist supervising the walking tests in a few cases had to walk close behind the participant. Thus, walking speed may have been affected, also affecting the distance covered. For practical reasons, we set an upper time limit at 15 minutes. Several of the participants actually walked until their legs gave away, but they were not represented among those participants where the test was stopped at 15 minutes. In that sense, the latter participants did not reach their absolute maximal walking distance limit. It is possible that the maximal walking distance could have been longer if the instructions did not encourage them to walk fast. However, encouragement to walk fast is recommended in the literature for PwMS (Goldman *et al*., [2008](#pri1625-bib-0007){ref-type="ref"}). All falls were self‐reported, which is a limitation, but on the other hand, prospectively reported, which is strength. The sample size was small, considering the heterogeneity of the outcome variables.

Implications for physiotherapy practise: {#pri1625-sec-0020}
----------------------------------------

People with MS often have impaired balance that may lead to falls.Falls often occur during walking.However, maximal walking distance and patient overestimate of walking capacity are not associated with falls.
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